Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19

NCT04416464 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2021-09-10

No results posted yet for this study

Summary

Patients suffering from pneumonia due to SARS-CoV-2 infection, after admission to the Intensive Care Unit (ICU), are susceptible to development of various functional sequelae, increased risk of chronic diseases, increased mortality rates and existence of relevant impacts on their quality of life in the months and years that follow the ICU admission. The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among patients recovered from SARS-COV-2 pneumonia, after discharge from the ICU, its determinants and predictors, in Portugal. It is a multicenter prospective cohort study of adult patients admitted at the ICU due to proven or suspected SARS-CoV-2 infection, included 90 days after discharge from the ICU. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. The secondary outcomes are all-cause mortality, rehospitalizations, return to work or study, the degree of dependence and functional capacity, symptoms of anxiety, depression and post-traumatic stress, level of physical activity and cognitive, renal and respiratory functions after ICU discharge. Investigators will collect data by means of structured telephone interviews, at a 12 months follow up period.

Conditions

  • Quality of Life
  • Long-term Outcomes
  • Coronavirus Infection
  • Morality
  • Rehospitalization

Interventions

OTHER

COVID-19 Pneumonia

Pneumonia due to proven or suspected SARS-Cov-2 infection

Sponsors & Collaborators

  • Centro Hospitalar De São João, E.P.E.

    collaborator OTHER
  • Centro Hospitalar do Porto

    collaborator OTHER
  • Universidade do Algarve

    collaborator OTHER
  • Centro Hospitalar Lisboa Ocidental

    collaborator OTHER_GOV
  • Universidade do Porto

    lead OTHER

Principal Investigators

  • Luís Filipe Azevedo, Prof. · Universidade do Porto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2021-07-31
Completion
2022-10-01

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416464 on ClinicalTrials.gov